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Abstract
Background: Malignant mesotheliomas (MM) have a poor prognosis, largely because of their chemoresistance to
anti-cancer drugs such as doxorubicin (Dox). Here we show using human MM lines that Dox activates extracellular
signal-regulated kinases (ERK1 and 2), causally linked to increased expression of ABC transporter genes, decreased
accumulation of Dox, and enhanced MM growth. Using the MEK1/2 inhibitor, U0126 and stably transfected shERK1
and shERK2 MM cell lines, we show that inhibition of both ERK1 and 2 sensitizes MM cells to Dox.
Results: U0126 significantly modulated endogenous expression of several important drug resistance (BCL2, ABCB1,
ABCC3), prosurvival (BCL2), DNA repair (BRCA1, BRCA2), hormone receptor (AR, ESR2, PPARg) and drug metabolism
(CYP3A4) genes newly identified in MM cells. In comparison to shControl lines, MM cell lines stably transfected with
shERK1 or shERK2 exhibited significant increases in intracellular accumulation of Dox and decreases in cell viability.
Affymetrix microarray analysis on stable shERK1 and shERK2 MM lines showed more than 2-fold inhibition (p ≤
0.05) of expression of ATP binding cassette genes (ABCG1, ABCA5, ABCA2, MDR/TAP, ABCA1, ABCA8, ABCC2)i n
comparison to shControl lines. Moreover, injection of human MM lines into SCID mice showed that stable shERK1
or shERK2 lines had significantly slower tumor growth rates in comparison to shControl lines after Dox treatment.
Conclusions: These studies suggest that blocking ERK1 and 2, which play critical roles in multi-drug resistance and
survival, may be beneficial in combination with chemotherapeutic drugs in the treatment of MMs and other
tumors.
Background
Malignant mesotheliomas (MMs), aggressive tumors
characterized by marked local invasiveness, are poorly
responsive to current therapeutic approaches. Clinical
outcomes for MM are poor, resulting in average patient
survival times of 7 to 12 months from initial diagnosis.
We hypothesized that chemotherapeutic agents used in
the treatment of MM activate survival pathways govern-
ing drug resistance [1]. For example, abnormal activa-
tion of the Raf/MEK/extracellular signal-regulated (ERK)
pathway occurs in many human cancers, including MM
[2], due to mutations in upstream membrane receptors,
Ras and B-Raf, as well as mutations in genes regulating
Raf activity that reportedly induces chemoresistance
to doxorubicin (Dox) and paclitaxel in breast cancer cells
[3]. Moreover, a phase II study in patients with MM
shows activation of both ERK and PI3K/AKT pathways
that are attributed to their resistance to erlotinib [4].
ERK activation has been identified as a potential survi-
val pathway in several tumor types [5], and recent stu-
dies show that ERKs may also be activated in response
to chemotherapeutic drugs [6-8] or mTOR inhibitors
[9]. We focused here on whether ERK1 and 2 played
critical roles in drug resistance and survival of MM, a
generally incurable cancer exhibiting marked chemore-
sistance. To understand the mechanisms involved, we
studied gene expression linked to drug resistance and
metabolism, including ATP binding cassette (ABC trans-
porters) genes. This large superfamily of membrane pro-
teins is comprised of 48 members that are divided into
7 different families based on sequence similarities [10].
We selected doxorubicin (Dox) (Adriamycin) for our
studies as this drug has been widely used as the most
successful drug of choice to treat MMs in single agent
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MMs [13,14]. The goal of this study was to understand
how Dox-induced resistance develops, and whether it can
be overcome by combination therapy. In the present
study we demonstrated that Dox treatment causes activa-
tion of survival signals (ERK1/2) in MM cells. Combined
treatment with a MEK1/2 inhibitor (U0126) plus Dox
increased MM cell death over levels observed with Dox
alone. Furthermore, using human MM lines expressing
shERK constructs, we show that both ERK1 and ERK2
contribute to Dox resistance in human MMs in vitro and
in vivo. Microarray and qRT-PCR analyses of these cell
lines revealed that ERK1 or 2 inhibition was linked to
decreases in mRNA levels of ATP binding cassette (ABC)
genes. Most importantly, we demonstrate that human
shERK1 and shERK2 stable MM lines (in comparison to
s h C o n t r o ll i n e s )h a v eas l o w e rg r o w t hr a t ea f t e rt r e a t -
ment with Dox in a SCID mouse xenograft model. These
data suggest that combined treatment using an ERK1/2
inhibitor or RNA interference approach with Dox (or
other chemotherapeutic drug) may be more beneficial
than single agent therapy in treatment of MMs.
Methods
Cell culture
None of the human malignant mesothelioma (MM)
lines described in this manuscript are commercially
available. However, they have been characterized pre-
viously by cell size, doubling time, immunohistochem-
ical analyses, electron microscopy, and chromosomal
karyotyping as reported (note that the names of these
lines have changed since originally reported)[15]. A sar-
comatoid (MO) and epithelioid (ME-26) human pleural
MM cell line were obtained from Drs. Luciano Mutti
(Maugeri Foundation, Pavia, Italy) and Maurizio Boc-
chetta (Loyola University, Mayfield, IL), respectively.
The HMESO MM line (epithelioid) was originally char-
acterized by Reale et al [16]. PPMMill, a sarcomatoid
human MM cell line, was obtained from Dr. Harvey
Pass (NYU School of Medicine, New York, NY). Human
mesothelial LP9/TERT-1 (LP9) cells, an hTERT-immor-
talized cell line phenotypically and functionally resem-
bling normal human mesothelial cells [17], were
obtained from Dr. James Rheinwald (Brigham and
Women’s Hospital, Harvard University, Boston, MA).
Prior to initiating the studies described here, all isolates
were confirmed as MM cells by immunohistochemistry
using an antibody to calretinin and verified for lack of
mycoplasma contamination using a polymerase chain
reaction. Additionally, Hmeso tumor xenografts grown
in SCID mice were resected and evaluated immunohis-
tochemically by Dr. Michele Carbone and shown to be
cytokeratin positive, indicating that they are mesothelial
origin. Subsequent karyotype analysis of the Hmeso line
by Dr. Joseph Testa demonstrated that the cells were
human and possessed several deletions common in
mesothelioma lines. These data support what was ori-
ginally reported for this MM line [16]. All cells were
maintained in 50:50 DMEM/F12 medium containing
10% FBS and supplemented with penicillin (50 units/ml),
streptomycin (100 μg/ml), hydrocortisone (100 μg/ml),
insulin (2.5 μg/ml), transferrin (2.5 μg/ml), and selenium
(2.5 μg/ml), incubated at 37°C in 5% CO2 and grown to
approximately 80-90% confluency [18]. The synthetic
MEK1/2 inhibitor, U0126, and its inactive analog,
U0124, were obtained from Calbiochem (La Jolla, CA)
and added to cells at 20 μM in medium containing
≤0.2% DMSO [18]. Control cultures received medium
without compounds but with vehicle (≤0.2% DMSO)
alone and were treated identically. Doxorubicin (Dox)
was obtained from Sigma (St Louis, MO).
Viability determination by cell counting
Viability of cells after Dox treatment was studied by plat-
ing cells at 1X10
5 per well in a 12 well plate. At conflu-
ence, cells were maintained in low serum containing
medium (0.5% FBS) for 24 h before treating them with dif-
ferent concentrations of Dox (0-100 μM) for 24 h. Cells
were trypsinized and counted using a hemocytometer.
MTS assay
Human MM cells (transfected or untransfected) were
treated with different concentrations of Dox with and
without U0126 or U0124 for 24 h, and cell viability was
measured in cells using the colorimetric MTS Assay,
CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega) as per the manufacturer’s recommen-
dations. Absorbance was read at 490 nm on a spectro-
photometer indicating MTS bioreduction to a colored
formazan product by viable cells.
Western blot analysis
To verify activation of ERK1/2 in MM cells after Dox
exposure with and without U0126 or U0124, Western
blots were performed as described previously [18] using
antibodies specific to pERK1/2 (rabbit polyclonal anti-
pERK1/2, 1:500, Cell Signaling Technology, Danvers,
MA), total ERK1/2 (rabbit polyclonal anti-ERK1/2,
1:1000, Cell Signaling Technology, Danvers, MA), and
total b-Actin 1:2000 (Abcam, Cambridge, MA). Western
blots were quantitated by the Quantity One program
[18] and normalized to total ERK1/2 levels. Western
blotting was also performed to validate the selective
inhibition of ERK1 or 2 in sh MM lines.
Preparation of RNA and PCR array analyses
LP9 and MM cells were grown to confluence and trea-
ted with U0126 (20 μM for 24 h). RNA was prepared
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CA). After quality assessment, 1 μgo fR N Aw a s
employed for cDNA synthesis using the RT
2 First
Strand Kit (SABiosciences, Frederick, MD). Quantitative
Real-Time PCR (qRT-PCR) was performed by the Ver-
mont Cancer Center DNA Analysis Facility using RT
2
Real-Time™ SYBR Green PCR Master Mix and Human
drug resistance and metabolism template RT
2 Profiler™
PCR Arrays (SABiosciences) (7900HT Sequence Detec-
tion System, Applied Biosystems). Data were analyzed
using an on-line spreadsheet-based data analysis tem-
plate (SABiosciences). qRT-PCR (TaqMan) was used to
validate selected genes using Assay on Demand (AOD)
Primers and Probes from Applied Biosystems.
Creation of shERK1 and shERK2 stable MM lines
HMESO cells were selected for these studies because these
cells are well-characterized [16] and form MMs reproducibly
after injection into SCID mice. Confluent HMESO cells
were transfected with either ERK1 or ERK2, or scrambled
control Sure Silencing Plasmids (4 sh sequences for each
gene were used) from SA Biosciences (Frederick, MD),
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After
selection for 14 days in G418 (400 μg/ml)-containing med-
ium, clones were screened by qRT-PCR for inhibition of
ERK mRNA levels as compared to scrambled control
(shControl) transfected clones. Two clones from each
shERK1 and shERK2 groups were processed by limited dilu-
tion to obtain clones in which individual ERKs were inhib-
ited by more than 70% in comparison to shControl clones.
Following this procedure, shERK1 and shERK2 clones exhi-
biting inhibition of >80% ERK expression were obtained.
Similarly, shERK1/2 lines were also created from PPMMill
lines to verify observations obtained with HMESO line. The
experimentally verified shRNA design algorithm (SABios-
ciences) assures gene-specificity and efficacy. An advanced
specificity search in addition to BLAST built into the algo-
rithm helped to reduce potential off-target effects.
Flow cytometry
To quantitate Dox fluorescence shControl (shCon),
shERK1 and shERK2 HMESO cells were grown to con-
fluence and then treated with Dox (0.5 or 5.0 μM) for 1
h or 5 h. Negative controls had no drug added. Cells
were washed 3X with phosphate-buffered saline (PBS),
trypsinized, counted, suspended in PBS, and Dox fluor-
escence was examined by flow cytometry using an LSRII
flow cytometer (BD Biosciences, MA). A 695/40-nm-
band-pass filter with a 685-nm long pass was used to
measure Dox fluorescence.
Fluorescence microscopy for Dox fluorescence
shControl, shERK1 and shERK2 cells were grown to
confluence in 4-chambered CultureSlides (BD Falcon,
Bedford, MA) in medium containing 10% FBS. Media
was replaced with that containing 0.5% FBS 24 h before
treatment. Cells were either untreated or treated with
0.5 or 5 μMD o xf o r1ho r5ha t3 7 ° C .S l i d e sw i t h
attached cells were then washed in PBS and fixed in
100% methanol for 20 min at -20°C. Slides were washed
in PBS and water, allowed to dry, and coverslipped
with Aqua Poly/Mount (Polysciences Inc., Warrington,
PA). Slides were then stored at 4°C until fluorescent
images were acquired using an Olympus BX50 Light
Microscope with attached mercury epi-fluorescence
illumination.
Affymetrix gene profiling
Microarrays were performed on MM cell samples from
3 independent experiments as described previously [19].
Each of the samples was analyzed on a separate array, i.
e., N = 3 arrays per MM line (3 independent biological
replicates). A Human U133A 2.0 array (Affymetrix,
Santa Clara, CA) was scanned twice (Hewlett-Packard
GeneArray Scanner), the images overlaid, and the aver-
age intensities of each probe cell compiled. Microarray
data were analyzed using GeneSifter software (VizX
Labs, Seattle, WA). This program used a “tt e s t ” for
pairwise comparison and a Benjamini-Hochberg test for
false discovery rate (FDR 5%) to adjust for multiple
comparisons. A 2-fold cut-off limit was used to assess
statistical significance.
Quantitative real time PCR (qRT-PCR)
To validate microarray profiles and PCR Array profiles
of genes, qRT-PCR (TaqMan) was performed as
described previously [19]. Triplicate assays were per-
formed with RNA samples isolated from at least 3 inde-
pendent experiments. Fold changes in gene expression
were calculated using the delta-delta Ct method using
hypoxanthine phosphoribosyl transferase (HPRT1)a s
t h en o r m a l i z a t i o nc o n t r o l .T h eA s s a yo nD e m a n dp r i -
mers and probes used were purchased from Applied
Biosystems (Foster City, CA).
Assessment of Dox effects on human tumors appearing
after injection of stably transfected shERK1, shERK2 and
shControl MM lines in a mouse xenograft model
HMESO cells stably transfected with either shERK1,
shERK2 or shControl were injected into 4 subcutaneous
sites (5 × 10
6 cells per injection site) on the dorsa of 6
wk old Fox Chase Severe Combined Immunodeficient
(SCID) mice (Jackson Laboratories, Bar Harbor, ME).
All mice (N = 6/group) were weighed weekly and exam-
ined every other day for morbidity and tumor growth
(measured using a digital caliper). Immediately after
tumor appearance (1 wk post cell injection) each group
was divided in two subgroups, each containing 3 mice.
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saline/tumor site) 3X weekly. The remaining 3 mice
from each group received saline (50 μl/tumor site) 3X
w e e k l y .T h eD o xd o s ea n df r e q u e n c yw e r ep r e v i o u s l y
determined to cause no toxicity to mice. After 6 wk of
treatment, all mice were weighed and euthanized by
intraperitoneal (ip) injection of sodium pentobarbital,
necropsied to determine possible gross metastases, and
major organs removed and stored in 4% paraformalde-
hyde before processing for histopathology. Tumors were
characterized using previously described histochemical
criteria [20] and karyotyped to prove that they were
human in origin. Tumor volumes were calculated using
formula (π × long axis × short axis × short axis)/6. All
experiments using mice were approved by the Institu-
tional Animal Care and Use Committee at the Univer-
sity of Vermont College of Medicine.
Statistical analyses
In all in vitro assays, at least 3 independent samples
were examined at each time point per group in dupli-
cate or triplicate experiments. Data were evaluated by
ANOVA using the Student Neuman-Keul’sp r o c e d u r e
for adjustment of multiple pairwise comparisons
between treatment groups or using the non-parametric
Kruskal-Wallis and Mann-Whitney tests. Differences
with p values ≤0.05 were considered statistically signifi-
cant. The difference in tumor growth rates between dif-
ferent groups in in vivo studies was assessed using a
hierarchical regression model to take into account the
correlation between repeated measurements on the
same tumor and multiple tumors in the same animal. In
this analysis, the regression coefficient describing tumor
growth is modeled as a function of treatment group as
well as random variation due to differences between ani-
mals and tumors on the same animal.
Results
Human MM lines show ERK1 and ERK2 activation in
response to low (< LD50) concentrations of Dox
Four MM lines (MO, ME-26, HMESO, PPMMill) were
treated with various concentrations (0-100 μM) of Dox
for 24 h to determine LD50 concentrations. As shown in
Figure 1A, a Dox concentration of 25 μMw a st h e
approximate LD50 concentration for MO and ME-26
lines whereas HMESO and PPMMill lines showed LD50
concentrations of approximately 100 μM or greater,
respectively (preliminary data not shown). After treat-
ment with various concentrations of Dox, cell lysates
were assessed for active (phosphorylated) and total
ERK1/2 levels by Western blot analysis. The MO line
showed a dose related increase in phosphorylation of
both ERK1 and ERK2 that was significant (p ≤ 0.05)
starting at the lowest concentrations (1 μM) of Dox
used. ME-26 and HMESO lines also showed significant
Dox-induced activation of ERK1 and 2 starting at 10
and 25 μM, respectively (Figure 1B), whereas PPMMill
cells showed comparable activation of ERK1 and 2 at
10-100 μM Dox. Pre-treatment of human MM cells
with the MEK1/2 inhibitor U0126 (20 μMf o r1h )
resulted in attenuation of Dox-induced ERK1/2 activa-
tion in all MM lines, whereas the inactive analog, U0124
(20 μM for 1 h), had no significant effects on Dox-
induced ERK phosphorylation (Figure 1C).
Dox-induced ERK1/2 activation promotes survival of
human MM cells
To assess the role of Dox-activated ERK1/2 in cell survi-
val, we pretreated human MM cells (MO, ME-26 and
HMESO) with the MEK1/2 inhibitor (U0126, 20 μM) for
1 h before treating for 24 h with Dox at 25 (MO, ME-26)
or 100 μM (HMESO), the approximate LD50 concentra-
tion for each cell type. The MTS assay then was per-
formed to determine cell viability. The higher
concentrations of Dox (equal to LD50 for various MM
cell types) were used for viability assays as lower concen-
trations of Dox, (1, 5, 25 μM) had no effect on cell viabi-
lity either alone or in combination with U0126 (data not
shown). As shown in Figure 2A (grey bars), treatment
with U0126 and Dox resulted in significantly more cell
killing in all 3 MM lines evaluated as compared to Dox
o rU 0 1 2 6a l o n e .I nH M E S Oa n dM Oc e l l s ,U 0 1 2 6a l o n e
also had a significant effect on reducing cell viability, sug-
gesting the possible role of endogenous ERK1/2 activa-
tion in cell survival. The inactive analog, U0124 (20 μM
for 1 h), had no toxic effects or modulation of Dox-
induced cell killing in any MM line, confirming the speci-
fic effects of the U0126, MEK1/2 inhibitor.
Human MM lines have high endogenous expression of
many prosurvival and drug resistance related genes
which are regulated by ERK1/2
A PCR Array using a ‘human cancer drug resistance and
metabolism’ template on 2 human MM lines (MO, ME-
26), compared to the nonmalignant LP9/TERT-1 human
mesothelial cell line, showed that both MM lines had
significantly (p ≤ 0.05) greater endogenous levels of
many prosurvival and drug resistance genes (Table 1
and Additional File 1, Table S1). Of the 10 most highly
expressed genes for each line listed in Table 1, mRNA
expression of 6 genes (BCL2, cFOS, MET, BRCA1, ESR2
and BRCA2) was common to both cell lines, whereas 6
genes were differentially expressed. mRNA levels of 2
common genes (BCL2 and cFOS) highly expressed in
each MM line were also validated by qRT-PCR (*p ≤
0.05 as compared to LP9/TERT-1 cells). In addition to
the genes listed in Table 1, many other genes were up-
or down-regulated significantly in both cell types and
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Page 4 of 13Figure 1 Human MM lines show ERK1/2 activation after exposures to Doxorubicin (Dox). A. Two different MM lines (MO and ME-26) were
treated with Dox (0-100 μM) for 24 h and cell viability was determined by the MTS assay as described in the ‘Materials and Methods’.* p≤ 0.05
as compared to control (0), N = 3-6 per group. B. Western blot analysis was performed using specific antibodies for pERK1/2 and total ERK1/2 as
described in the ‘Materials and Methods’. Both ERK1 and ERK2 were activated (see pERK1 and pERK2) in response to Dox; however, total ERK1
and 2 remained unchanged. *p ≤ 0.05 as compared to respective controls. N = 2 per group. HMESO MM line showed very little ERK1 and pERK1
as compared to other cell lines. C. Dox-activated ERK1/2 in different MM lines is attenuated by the MEK1/2 inhibitor U0126 (20 μM, for 1 h),
whereas its inactive analog U0124 is ineffective. *p ≤ 0.05 as compared to respective untreated (0) controls. †p ≤ 0.05 as compared to Dox
treated groups. N = 2 per group.
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Page 5 of 13Figure 2 Dox-induced ERK1/2 activation promotes survival of human MM cells. A. Three MM lines (MO, ME-26 and HMESO) were
pretreated with U0126 or U0124 (20 μM, 1 h) before treating them with an LD50 dose of Dox for 24 h. Cell viability was assessed using the MTS
assay as described in ‘Materials and Methods’. A combined treatment of U0126 and Dox caused significantly increased cell death as compared to
either treatment alone (grey bars). *p ≤ 0.05 as compared to untreated control. †p ≤ 0.05 as compared to Dox alone group. N = 3-6 per group.
B. HMESO or PPMMill cells were stably transfected with either shERK1 or shERK2 as described in the ‘Materials and Methods’. These stable MM
lines were treated with Dox (100 μM) for 24 h and cell viability was assessed using the MTS assay or cell counting. Inhibition of ERK1 or ERK2
significantly enhanced Dox-induced cell killing. *p ≤ 0.05 as compared to respective untreated control. †p < 0.05 as compared to Dox treated
shControl (shCon). ‡p ≤ 0.05 as compared to shERK1 Dox group. N = 6 per group.
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Page 6 of 13are listed separately in Additional Table 1. Exposure of
both MM cell lines to the MEK1/2 inhibitor (U0126, 20
μM for 24 h) resulted in significantly altered levels of
some of these genes (BCL2, cFOS, BRCA1, AR, ESR2,
CYP3A4, PPARg, BRCA2, ABCC3)( T a b l e1a n dA d d i -
tional Table 1), suggesting a role of ERK1 or 2 in their
regulation.
Inhibition of either ERK1 or ERK2 sensitizes MM cells to
Dox
As the small molecule inhibitor, U0126, abrogated both
ERK1 and ERK2 activation, we created stably inhibited
(short hairpin, sh) ERK1 and ERK2 HMESO and
PPMMill lines to determine if ERKs had similar or
unique roles in Dox chemoresistance. The human
Table 1 PCR Array analysis† showing top 10 endogenously upregulated (p ≤ 0.05) genes in human MM cell lines (MO,
ME-26) compared to untransformed LP9/TERT1 mesothelial cells
Gene name (symbol) Function Fold Increase (MO) Fold Increase (ME-26)
-UO126 +UO126
20 μM
-UO126 +UO126
20 μM
B-cell CLL/Lymphoma (BCL2)* Drug Resistance 213.65 127.7
§ 28.92 14.57
§
V-fos FBJ murine osteosarcoma viral oncogene homolog
(FOS)*
Transcription Factor 26.52 2.28
§ 33.85 20.59
§
Met protooncogene (MET) Growth Factor
Receptor
25.45 28.09 27.60 25.42
ATP-binding cassette (MDR/TAP) (ABCB1) Drug Resistance 13.6 4.66
Estrogen receptor 1 (ESR1) Hormone Receptors 11.03 10.90
Breast cancer 1, early onset (BRCA1) DNA Repair 6.66 1.42
‡,§ 6.68 2.88
§
Androgen receptor (AR) Hromone Receptors 6.35 10.25
§
Estrogen receptor 2 (ESR2) Hormone Receptor 4.19 10.48
§ 4.53 6.15
Breast cancer 2, early onset (BRCA2) DNA Repair 3.98 2.21 5.18 2.64
§
Cyclin-dependent kinase inhibitor 2D (CDKN2D) Cell Cycle 3.68
‡ 4.88
Cytochrome P450 (CYP3A4) Drug Metabolism 77.12 25.06
§
Peroxisome proliferative activated receptor, gamma (PPARg) Hormone Receptor 9.72 4.55
§
Tumor protein 53 (TP53) Drug Resistance 4.35 4.52
ATP-binding cassette (ABCC3) Drug Resistance 4.56 2.26
§
*Validation by qRT-PCR
Gene name (symbol) Function Validation (MO) Validation (ME-26)
-UO126 +UO126 -UO126 20
μM
+UO126 20 μM
B-cell CLL/Lymphoma (BCL2) Drug Resistance 550 476 123 31
V-fos FBJ murine osteosacroma viral oncogene homolog
(FOS)
Transcription Factor 16 2.14 23.88 8.9
†SABiosciences: Human drug resistance and metabolism template
‡Not significantly different from LP9
§Significantly different from -UO126 group of the respective cell line
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Page 7 of 13HMESO and PPMMill MM lines were selected for this
purpose as these lines were most insensitive (resistant) to
Dox. A significant inhibition (≥70%) of ERK1 or ERK2 in
respective lines was obtained as confirmed by Western
blotting. In initial in vitro experiments, stable shERK1,
shERK2 or shControl (shCon) MM lines were treated
with Dox (100 μM, ~LD50 dose) for 24 h, and cell viabi-
lity was assessed by the MTS assay (HMESO) or by cell
counting (PPMMill). As shown in Figure 2B, shERK1 and
shERK2 cell lines showed significantly attenuated cell via-
bility after Dox treatment as compared to shControl lines
(Figure 2B, *p ≤ 0.05 as compared to respective untreated
control; †p ≤ 0.05 as compared to Dox treated shCon-
trol). Although significantly increased Dox-induced cell
killing was observed after inhibition of either ERK1 or
ERK2, the shERK2 cell lines showed significantly (‡p ≤
0.05) greater cell killing as compared to the shERK1 lines
from both MMs (Figure 2B). The shCon line, as dis-
cussed in the ‘Material and Method’ section, contains a
vector with a scrambled sequence, which does not inhibit
any gene. shCon cells are expected to behave like
untransfected cells as they do in our experiments (com-
pare HMESO in Figure 2A and 2B).
Inhibition of ERK1 or ERK2 results in greater
accumulation of Dox in MM cells
To show that inhibition of ERK1 or ERK2 increases
Dox-induced toxicity by causing greater intracellular
accumulation of Dox, we performed flow cytometry
experiments on stably transfected HMESO lines treated
with Dox (0.5 or 5.0 μM for 1 h or 5 h). Figure 3A
shows that MM cell lines stably transfected with either
shERK1 or shERK2 exhibited significant dose- and time-
related increases in accumulation of intracellular Dox as
compared to shControl cells treated with Dox at both
time points (*p ≤ 0.05 as compared to respective shCon-
trol group). Dox at the low concentration (0.5 μM
for1h) was retained marginally but significantly in the
ERK1-inhibited (shERK1) HMESO line, whereas high
Dox (5 μM for1 and 5 h) was retained by both ERK1
and ERK2-inhibited HMESO (sh) lines as compared to
the shCon line treated with Dox. Data in Figure 3A cor-
relate well with findings shown in Figure 2B, where Dox
at the high concentration (100 μM for 24 h) shows
reduced viability in the shERK2 group. Although Dox
retention in both shERK1 and shERK2 groups was simi-
lar, the increased toxicity of Dox in the shERK2 group
(Figure 2B, HMESO) could be attributed to additional
factors. Figure 3B confirms the patterns of Dox accumu-
lation by fluorescence microscopy in MM cells. Note the
lack of Dox in the 0 (untreated groups) and the dose-
related increases in intracellular fluorescence present in
the shERK1 and shERK2 cells.
Effect of ERK1 or ERK2 inhibition on ATP binding cassette
genes (ABC transporters) in MM cells
Based on data above and in Table 1, we next hypothe-
sized that ERKs modulated endogenous expression of
ABC cassette genes that function to pump Dox and
other chemotherapeutic drugs out of tumor cells, result-
ing in their decreased drug sensitivity. To address this
hypothesis, we performed microarray analysis on
shERK1, shERK2 and shControl HMESO cells (no expo-
sure to Dox). Table 2 provides a list of 7 ABC genes
(many involved in Dox transport) that had decreased
mRNA levels in shERK1 and shERK2 cell lines. Valida-
tion of several changes in gene expression was per-
formed using qRT-PCR (*Table 2, p ≤ 0.05 as compared
to shControl). We also examined endogenous levels of
A B Ct r a n s p o r t e rg e n e si nH M E S OM Mc e l l sa sc o m -
pared to nontransformed human mesothelial cells LP9/
TERT-1 (p ≤ 0.05) (Table 3). These results showed that
HMESOs showed striking decreases (> 100 fold) in
mRNA levels of ABCG2 and ABCA1 as well as signifi-
cant decreases in ABCA8, ABCC3, ABCB1, ABCG1 and
ABCC4 expression, whereas other genes (MDR/TAP,
ABCA2, ABCC5 and ABCA7) were upregulated.
Tumors developing from shERK1 and shERK2 MM lines in
a mouse xenograft model show decreased tumor growth
rate after treatment with Dox
To verify the functional effects of ERK inhibition and
Dox treatment on tumor cell killing, we injected stable
shERK1, shERK2 or shControl HMESO MM cells sub-
cutaneously into SCID mice, and treated various groups
with Dox or saline at the tumor site as soon as tumors
appeared (1 wk post cell inoculation, 3X weekly) for a 6
wk period. As shown in Figure 4, Dox significantly
reduced the rate of tumor growth in all three animal
groups compared to saline treatment, with the largest
reduction occurring in the shControl group. In addition,
Dox-treated animals in the shERK1 or shERK2 groups
had significantly slower tumor growth than the Dox-
treated animals in the shControl group. The differences
between the shControl Dox-treated and shERK1 Dox-
treated tumor growth rates occurred prior to 21 days
post MM cell injection. All conclusions were derived by
statistical analysis (described in the Method section)
performed on different groups to compare alterations in
tumor growth rate and not tumor volume.
Discussion
Treatment of various MM lines with doses of Dox much
lower than LD50 concentrations resulted in phosphoryla-
tion of ERK1 and 2, the most abundant ERKs in mamma-
lian cells. In addition to Dox, many other anti-cancer drugs
such as paclitaxel and cisplatin induce activation of ERKs
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ERK activation in different cell types depending upon
experimental conditions [23]. In our study, Dox-induced
ERK1/2 activation protected MM cells from Dox-induced
cell death, as shown when MM lines were pretreated
with the MEK1/2 inhibitor, U0126, prior to Dox exposure
(Figure 2). In support of our findings, it has been reported
that, in most cases, ERK activation protects cells from
drug-induced cell death [23,24], while in some tumor cells,
ERK activation contributes to cell death [21,22]. These dif-
ferent effects may be explained by differences in subcellular
distribution of specific ERKs, the longevity of ERK signal-
ing, or phosphorylation of different substrates which may
dictate death or survival [25].
Figure 3 Inhibition of ERK1 or ERK2 results in more accumulation of Dox in HMESO cells. A. HMESO cells stably transfected with either
shERK1 or shERK2 and shControl cells were treated with 0.5 or 5 μM of Dox for 1 or 5 h, and intracellular accumulation of Dox was measured
by flow cytometry as described in ‘Materials and Methods’. shERK1 or shERK2 HMESO lines show enhanced accumulation of Dox as compared to
shControl lines. *p ≤ 0.05 as compared to respective shControl (shCon). N = 2 per group. B. Fluorescence microscopic representation of dose-
related Dox accumulation (orange) in stably transfected HMESO cells after 1 h of treatment. All images are at 400X magnification (Bar = 50 μm).
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after ERK1/2 manipulation either with an inhibitor
(U0126) or by shRNA approaches. With the use of the
ERK1/2 inhibitor (inhibits both ERK1 and 2), HMESO
cells were the best responders (most susceptible) as
compared to MO and ME-26 (both lines showed the
same susceptibility) (Figure 2A). A shRNA approach to
inhibit either ERK1 or ERK2 was studied in 2 MM lines
(HMESO and PPMMill). Of the two lines studied by
this approach, HMESO again showed more sensitivity to
Dox-induced killing after ERK1 or ERK2 inhibition as
compared to PPMMill (Figure 2B). In addition, in both
Table 2 Microarray analysis showing endogenous expression of ATP-binding cassette genes in shERK1 and shERK2
cells compared to shControl, stable HMESO cells (p ≤ 0.05)
Gene name(symbol) Fold Change shERK1 vs. shCon Fold Change shERK2 vs. shCon
ATP-binding cassette, subfamily G (WHITE), member 1 (ABCG1) -4.89
ATP-binding cassette, subfamily A (ABC1), member 5 (ABCA5)* -2.77
ATP-binding cassette, subfamily A (ABC1), member 2 (ABCA2)*
† -2.13
Transporter 2, ATP-binding cassette, subfamily B (MDR/TAP)† -2.09
ATP-binding cassette, subfamily A (ABC), member 1 (ABCA1) -2.06
ATP-binding cassette, subfamily A (ABC1), member 8 (ABCA8)* -2.38
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 (ABCC2)*
† -2.19
*Validation by qRT-PCR
Gene name(symbol) Fold Change shERK1 vs. shCon Fold Change shERK2 vs. shCon
ABCA2 -2.88
ABCA5 -3.6
ABCA8 -3.4
ABCC2 -3.0
† Indicates Doxorubicin is a substrate as reported in the literature.
Table 3 Microarray analysis showing endogenous levels
of ATP-binding cassette genes in HMESO MM cells as
compared to normal mesothelial cells (LP9/TERT-1) (p ≤
0.05)
Gene symbol Fold Change
ABCG2 -125
ABCA1 -102
ABCA8 -16
ABCC3 -8
ABCB1 -3.8
ABCG1 -2.2
ABCC4 -2.1
Transporter 2, ABCB (MDR/TAP) 3.4
ABCA2 2.7
ABCC5 2.5
ABCA7 2.5
Figure 4 ERK inhibited tumors in a mouse xenograft model
show enhanced sensitivity to Dox. HMESO cells (5 × 10
6) stably
transfected with shERK1, skERK2, or shControl (shCon) constructs
were injected subcutaneously at 4 dorsal sites on SCID mice. Eight
days after cell injections, localized Dox or saline injections (6 μg/50
μl/tumor, 3 times a wk for 6 wks) were started (shown by arrow
heads). At autopsy, tumors were harvested and volumes were
calculated as described in ‘Materials and Methods’. N = 3 mice/
group, or 12 tumors/group. Statistical analysis (see Materials and
Methods) performed showed that Dox-treated mice in the shERK1
or shERK2 groups had significantly slower tumor growth than the
Dox-treated mice in the shControl group. All conclusions were
derived by statistical analysis (described in the Method section)
performed on different groups to compare alteration in tumor
growth rate and not tumor volume.
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inhibition in Dox-induced cell killing (Figure 2B).
Although regulation of apoptotic pathways has been
implicated in resistance of many cancers to chemother-
apy, we show that human MM lines endogenously over-
express many prosurvival genes (BCL2, cFOS, MET,e t c . )
in comparison to nontransformed mesothelial cells. The
increased levels of these commonly upregulated genes, as
reported by our lab and others [18,26-29] may in part be
responsible for drug resistance in MM cell lines. For
example, BCL2 and BCL-xL antisense treatment facili-
tates apoptosis in mesothelioma cells, suggesting BCL2/
BCL-xL bispecific antisense treatment in combination
with cisplatin or gecitabine may result in a more effective
therapy of MM [30]. Consistent with our findings, ERK1/
2 activation has been linked to expression and activation
of BCL2 in various systems [3,31] resulting in an anti-
apoptotic or survival outcome. cFOS, a protooncogene
and component of activator protein-1 (AP-1), is upregu-
lated by crocidolite asbestos in rat pleural mesothelial
cells [32], and endogenously upregulated in human
mesothelioma cell lines and tumors [18,28]. We show for
the first time that BRCA1 and BRCA2 are endogenously
overexpressed in MM cells, and are pursuing their muta-
tion and functional status in various MMs. ERK1/2 has
been linked to feedback regulation of the tumor suppres-
sor/DNA repair gene BRCA1 in irradiation induced DNA
damage checkpoint activation [33,34]. BRCA2 was also
endogenously upregulated in MM cells and ERK1/2 inhi-
bition decreased expression of this gene (Table 1), consis-
tent with already published work that ERK1/2 activation
inhibits replication of prostate cells via upregulation of
BRCA2 [35]. Another gene, PPARg, which was upregu-
lated only in ME-26 and was significantly inhibited by
the U0126 MEK1/2 inhibitor is activated via an ERK1/2
dependent COX-2 pathway in macrophages [36]. Inflam-
matory pathways involving PPARg or COX-2 are promis-
ing therapeutic targets in a number of cancers [37]. We
also report for the first time the upregulation of a cyto-
chrome P450 enzyme gene, CYP3A4, related to drug
metabolism in the ME-26 epithelioid cell line that was
decreased 3-fold after addition of U0126. The presence of
the androgen receptor and its endogenous expression in
sarcomatoid MM cells is also a novel finding, and both
AR and ESR2 have been linked to the ERK pathway
[38-40] as shown in Table 1 in MO cells. A recent study
suggests that ER-b affects the prognosis of MM by acting
as a tumor suppressor [41].
ATP-binding cassette (ABC) transporters transport var-
ious molecules, including chemotherapeutic drugs, across
extra- and intracellular membranes. Increased expression
of one or more of these proteins is seen in almost all
resistant cancers and is considered responsible fully or in
part for the observed drug resistance in most cancer cell
lines. In a previous study using MM cell lines, coordinated
overexpression of the multi drug resistance pump (MRP)
and gamma-glutamylcysteine synthetase genes, but not
MDR1, correlated with Dox resistance [42]. In the 3 MM
lines we studied by PCR array or microarray analysis, dif-
ferent types of ABC transporter genes were endogenously
overexpressed as compared to untransformed LP9/TERT-
1 mesothelial cells (Table 1, Table 3). The overexpression
of different types of ABC genes in different MM cells
further confirms the highly heterogenic nature of MM
tumors that vary widely in their prognosis and response to
therapy. Inhibition of ABC genes by ERK1 or 2 inhibition
may be responsible for the increased accumulation of Dox
observed in shERK1 and shERK2 MM cells (Figure 3).
Among ABC genes inhibited by shERK2 in HMESO cells,
ABCA8 is a relatively uncharacterized new transporter
[43] whereas Dox is a known substrate for ABCC2,
ABCA2 and MDR/TAP [44-46]. Our data suggest that dif-
ferent ERKs regulate distinct ABC genes, and a detailed
study is needed to understand the roles of different ERKs,
including ERK5 that has been linked to chemoresistance
in breast cancers [47], in ABC gene regulation. Consistent
with our studies, ERK1 and 2 are linked to regulation of
many ABC genes, including ABCG1, ABCA1, MDR1, and
MRP1 in various cancer and non-cancer cells [6,48-50].
Conclusions
Our in vitro and in vivo studies here indicate that both
ERK1 and ERK2 play significant roles in imparting Dox
resistance to MM cells by modulating genes related to
drug resistance and survival previously unidentified in
MM cells. Most importantly, we demonstrate that gene
expression of distinct ABC transporters is modulated by
blocking ERK1 or ERK2, and show the relationship of
these phenomena to Dox accumulation in human MM
cells. Further, we demonstrate that blocking ERK1 and
ERK2 enhances the chemotherapeutic potential of Dox in
a murine xenograft model. The mechanisms of ERK1/2
action appear to involve both upregulation of prosurvi-
val/antiapoptotic genes as well as ABC transporter genes.
Based on our observations, ERK1/2 inhibitors in combi-
nation with chemotherapeutic drugs might be a better
option to treat patients with MM than drugs alone.
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